Publisher
Springer International Publishing
Reference48 articles.
1. Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R et al (2016) Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications. Mol Cancer Ther 15(4):628–639
2. Bedi S, Khan SA, AbuKhader MM, Alam P, Siddiqui NA, Husain A (2018) A comprehensive review on Brigatinib – a wonder drug for targeted cancer therapy in non-small cell lung cancer. Saudi Pharm J 26(6):755–763
3. Cho BC, Kim DW, Bearz A, Laurie SA, McKeage M, Borra G et al (2017) ASCEND-8: a randomized phase 1 Study of Ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 12(9):1357–1367
4. Cholewka-Stafinska M, Polaniak R, Kardas M, Grajek M, Grochowska-Niedworok E (2017) Interaction of oral form anticancer drugs with grapefruit juice. Pol Merkur Lekarski 42(247):30–33
5. European Medicines Agency EMA (2022a) Assessment report. Disponibile on line: https://www.ema.europa.eu/en/documents/assessment-report/alecensa-epar-public-assessment-report_en.pdf. Last access 9 Sept 2022